These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Somatic alterations as the basis for resistance to targeted therapies. Blair BG; Bardelli A; Park BH J Pathol; 2014 Jan; 232(2):244-54. PubMed ID: 24114654 [TBL] [Abstract][Full Text] [Related]
3. The genetic complexity of common cancers and the promise of personalized medicine: is there any hope? Arnedos M; Vielh P; Soria JC; Andre F J Pathol; 2014 Jan; 232(2):274-82. PubMed ID: 24114621 [TBL] [Abstract][Full Text] [Related]
4. The changing face of percutaneous image-guided biopsy: molecular profiling and genomic analysis in current practice. Marshall D; Laberge JM; Firetag B; Miller T; Kerlan RK J Vasc Interv Radiol; 2013 Aug; 24(8):1094-103. PubMed ID: 23806383 [TBL] [Abstract][Full Text] [Related]
5. Recent advances and current issues in single-cell sequencing of tumors. Sun HJ; Chen J; Ni B; Yang X; Wu YZ Cancer Lett; 2015 Aug; 365(1):1-10. PubMed ID: 26003306 [TBL] [Abstract][Full Text] [Related]
6. Array-based pharmacogenomics of molecular-targeted therapies in oncology. Sanoudou D; Mountzios G; Arvanitis DA; Pectasides D Pharmacogenomics J; 2012 Jun; 12(3):185-96. PubMed ID: 22249357 [TBL] [Abstract][Full Text] [Related]
7. Next generation sequencing reveals genetic landscape of hepatocellular carcinomas. Li S; Mao M Cancer Lett; 2013 Nov; 340(2):247-53. PubMed ID: 23063663 [TBL] [Abstract][Full Text] [Related]
8. Impact of tumor sequencing on the use of anticancer drugs. Thomas F; Desmedt C; Aftimos P; Awada A Curr Opin Oncol; 2014 May; 26(3):347-56. PubMed ID: 24709974 [TBL] [Abstract][Full Text] [Related]
9. Biology-driven phase II trials: what is the optimal model for molecular selection? Andre F; Delaloge S; Soria JC J Clin Oncol; 2011 Apr; 29(10):1236-8. PubMed ID: 21343554 [No Abstract] [Full Text] [Related]
10. The challenge of intratumour heterogeneity in precision medicine. Seoane J; De Mattos-Arruda L J Intern Med; 2014 Jul; 276(1):41-51. PubMed ID: 24661605 [TBL] [Abstract][Full Text] [Related]
11. Synthetic lethal vulnerabilities of cancer. Fece de la Cruz F; Gapp BV; Nijman SM Annu Rev Pharmacol Toxicol; 2015; 55():513-31. PubMed ID: 25340932 [TBL] [Abstract][Full Text] [Related]
13. Clinical applications of The Cancer Genome Atlas project (TCGA) for squamous cell lung carcinoma. Devarakonda S; Morgensztern D; Govindan R Oncology (Williston Park); 2013 Sep; 27(9):899-906. PubMed ID: 24282988 [TBL] [Abstract][Full Text] [Related]
14. Whole-exome sequencing reveals recurrent somatic mutation networks in cancer. Liu X; Wang J; Chen L Cancer Lett; 2013 Nov; 340(2):270-6. PubMed ID: 23153794 [TBL] [Abstract][Full Text] [Related]
15. Next generation sequencing applications in cancer research. Zhang W; Nykter M; Chen K Cancer Lett; 2013 Nov; 340(2):149-50. PubMed ID: 23764479 [No Abstract] [Full Text] [Related]
16. Cancer heterogeneity and "the struggle for existence": diagnostic and analytical challenges. Horswell S; Matthews N; Swanton C Cancer Lett; 2013 Nov; 340(2):220-6. PubMed ID: 23142290 [TBL] [Abstract][Full Text] [Related]
17. Genomics, personalized medicine and cancer practice. Dancey J Clin Biochem; 2012 Apr; 45(6):379-81. PubMed ID: 22424082 [No Abstract] [Full Text] [Related]
18. Implementing genomic medicine in pathology. Williams ES; Hegde M Adv Anat Pathol; 2013 Jul; 20(4):238-44. PubMed ID: 23752086 [TBL] [Abstract][Full Text] [Related]
19. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology]. Ludwig WD Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103 [TBL] [Abstract][Full Text] [Related]
20. Understanding genomic alterations in cancer genomes using an integrative network approach. Wang E Cancer Lett; 2013 Nov; 340(2):261-9. PubMed ID: 23266571 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]